Successful Treatment of Pityriasis Rubra Pilaris with Brodalumab

Main Article Content

Umair Khan
Nahla Shihab
Robert G Phelps
Mark Lebwohl

Keywords

pityriasis rubra pilaris, brodalumab, methotrexate

Abstract

Pityriasis Rubra Pilaris (PRP) is a rare inflammatory skin disease with highly variable clinical appearance. Treatment of PRP remains a challenge and has been mostly guided by case reports and case series. We report the first case of pityrisis rubra pilaris that is successfully treated with combination therapy of brodalumab and methotrexate.

References

1. Wang, D., Chong, V.CL., Chong, WS. et al. Am J Clin Dermatol (2018) 19: 377. https://doi.org/10.1007/s40257-017-0338-1

2. Roenneberg, S, Biedermann, T. Pityriasis rubra pilaris: algorithms for diagnosis and treatment. J Eur Acad Dermatol Venereol 2018; 32( 6): 889– 898.

3. Griffiths, W. (1980), Pityriasis rubra pilaris*. Clinical and Experimental Dermatology, 5: 105-112. doi:10.1111/j.1365-2230.1980.tb01676.x

4. Ross NA, Chung H, Li Q, Andrews JK, Keller MS, Vitto J. Epidemiologic, clinicopathologic diagnostic and management challenges of pityriasis rubra pilaris: a case series of 103 patients. JAMA Dermatol. 2016;152(6):670-675

5. Wain T, Choy B, Satchell AC, Woods JA, Frew JW. Secukinumab in pityriasis rubra pilaris: A case series demonstrating variable response and the need for minimal clinical datasets. JAAD Case Rep. 2018;4(5):500–505. Published 2018 May 7. doi:10.1016/j.jdcr.2018.02.007

6. Albert, M. R. and Mackool, B. T. (1999), Pityriasis rubra pilaris. International Journal of Dermatology, 38: 1-11. doi:10.1046/j.1365-4362.1999.00513

7. Klein A, Landthaler M, Karrer S. Pityriasis Rubra Pilaris. American Journal of Clinical Dermatology. 2010;11(3):157–170. doi:10.2165/11530070

8. Feldmeyer L, Mylonas A, Demaria O, et al. Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol. 2017;153(4):304-308.

9. Barth, D. , Harth, W. , Treudler, R. and Simon, J. C. (2009), Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 7: 1071-1073. doi:10.1111/j.1610-0387.2009.07154.x

10. Wasilewska A, Winiarska M, Olszewska M, Rudnicka L. Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. Postepy Dermatol Alergol. 2016;33(4):247–252. doi:10.5114/ada.2016.61599

11. Napolitano M, Abeni D, Didona B. Biologics for pityriasis rubra pilaris treatment: A review of the literature. Journal of the American Academy of Dermatology. 2018;79(2):353-359.e11. doi:10.1016/j.jaad.2018.03.036

12. Moretta G, De Luca EV, Di Stefani A. Management of refractory pityriasis rubra pilaris: challenges and solutions. Clin Cosmet Investig Dermatol. 2017;10:451–457. Published 2017 Nov 9. doi:10.2147/CCID.S124351